Your browser doesn't support javascript.
loading
Plasma cell leukemia: from biology to treatment.
Jelinek, Tomas; Kryukov, Fedor; Rihova, Lucie; Hajek, Roman.
Afiliação
  • Jelinek T; University Hospital Ostrava, Department of Haematooncology, Ostrava, Czech Republic.
  • Kryukov F; University of Ostrava, Faculty of Medicine, Ostrava, Czech Republic.
  • Rihova L; University Hospital Brno, Department of Clinical Haematology, Brno, Czech Republic.
  • Hajek R; University Hospital Ostrava, Department of Haematooncology, Ostrava, Czech Republic.
Eur J Haematol ; 95(1): 16-26, 2015 Jul.
Article em En | MEDLINE | ID: mdl-25778450
ABSTRACT
Plasma cell leukemia (PCL) is a very aggressive and rare form of malignant monoclonal gammopathy characterized by the presence of plasmocytes in peripheral blood. It is classified as primary PCL occuring 'de novo', or as secondary PCL in patients with relapsed/refractory multiple myeloma. Primary PCL is a distinct clinicopathological entity from myeloma with different cytogenetic abnormalities and molecular findings, which are usually found only in advanced multiple myeloma. The clinical course is aggressive with short remissions and reduced overall survival. The diagnostic criteria are based on the percentage (>20%) and absolute number (2 × 10(9) /L) of plasma cells in peripheral blood. After establishing diagnosis, induction therapy should begin promptly which is aimed to rapid disease control and to minimize the risk of early death. Intensive chemotherapy regimens and bortezomib-based regimens, followed by high-dose therapy with autologous stem cell transplantation, are recommended. Allogeneic transplantation can be considered in younger patients. This article reviews recent knowledge of this hematological malignancy that is associated with a very poor prognosis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Plasmocitária / Protocolos de Quimioterapia Combinada Antineoplásica / Aberrações Cromossômicas / Transplante de Células-Tronco / Bortezomib / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Eur J Haematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: República Tcheca

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Plasmocitária / Protocolos de Quimioterapia Combinada Antineoplásica / Aberrações Cromossômicas / Transplante de Células-Tronco / Bortezomib / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Eur J Haematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: República Tcheca